Pros and cons for use of statins in people with coronavirus disease-19 (COVID-19).
Diabetes Metab Syndr
; 14(5): 1225-1229, 2020.
Article
in English
| MEDLINE | ID: covidwho-640010
ABSTRACT
BACKGROUND AND AIMS:
Morbidity and mortality from coronavirus disease 2019 (COVID-19) is higher among people with diabetes mellitus (DM), hypertension, and cardiovascular disease (CVD). Statins are used in the majority of people with DM and CVD. This mini-review discusses the current understanding of benefit-risk ratio of use of statins in COVID-19.METHODS:
We searched PubMed database using specific keywords related to our aims till June 12, 2020. Full text of relevant articles published in English language were retrieved and reviewed.RESULTS:
Statins, with their immunomodulatory, anti-inflammatory, anti-thrombotic, and anti-oxidant properties, have the potential to reduce severity of lung injury in, and mortality from, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2) infections. Statin-induced upregulation of angiotensin-converting enzyme-2 (ACE2) has the potential to reduce lung injury from excess angiotensin II. By disrupting lipid rafts, statins have the potential to reduce viral entry into cells. However, benefit-risk ratio of its complex interaction with MYD88 gene expression on outcomes in COVID-19, and the putative role of low serum LDL cholesterol in increasing severity of SARS-CoV2 infection need further clarification.CONCLUSIONS:
People with COVID-19, who are already on statins for an underlying co-morbid condition, should continue on it unless there are specific contraindications. De-novo use of statins in people with COVID-19 with no underlying co-morbidity might be beneficial but awaits substantiation in clinical trials; till that time, de novo use of statins in COVID 19 should be limited to a clinical trial setting.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Hydroxymethylglutaryl-CoA Reductase Inhibitors
/
Pandemics
/
Betacoronavirus
Type of study:
Observational study
/
Prognostic study
/
Randomized controlled trials
/
Reviews
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Diabetes Metab Syndr
Year:
2020
Document Type:
Article
Affiliation country:
J.dsx.2020.07.011
Similar
MEDLINE
...
LILACS
LIS